NasdaqGS:ELVNPharmaceuticals
Is Enliven Therapeutics (ELVN) Fully Priced As Earnings Losses Meet A Sharp Stock Rally?
Enliven Therapeutics earnings update and what it means for the stock
Enliven Therapeutics (ELVN) recently reported second quarter and six month results to 30 June 2026. The company posted a quarterly net loss of US$32.49 million and a six month net loss of US$56.11 million.
Basic loss per share from continuing operations held at US$0.49 for the quarter compared with the same period last year. Over the six month period, basic loss per share from continuing operations was US$0.87 compared with...